Skip to main content
Eric Klein, MD, Urology, Cleveland, OH

Eric A Klein MD

Surgical Oncology


Chairman of the Glickman Urological & Kidney Institute and a staff member in the Taussig Cancer Institute at Cleveland Clinic

Join to view full profile
  • 9500 Euclid AveCleveland, OH 44195

  • Phone+1 800-223-2273

Dr. Klein is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • UPMC Medical Education
    UPMC Medical EducationResidency, Urology, 2021 - 2026
  • New York Presbyterian Hospital (Cornell Campus)
    New York Presbyterian Hospital (Cornell Campus)Residency, Urology, 1986 - 1988
  • Cleveland Clinic Foundation
    Cleveland Clinic FoundationResidency, Urology, 1981 - 1986
  • University of Pittsburgh School of Medicine
    University of Pittsburgh School of MedicineClass of 1981

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2003 - Present
  • OH State Medical License
    OH State Medical License 1984 - 2026
  • NY State Medical License
    NY State Medical License 2003 - 2022
  • MI State Medical License
    MI State Medical License 2001 - 2021
  • IL State Medical License
    IL State Medical License 2003 - 2020
  • NV State Medical License
    NV State Medical License 2013 - 2017
  • PA State Medical License
    PA State Medical License 2002 - 2008
  • Urology
    American Board of Urology Urology
  • Join now to see all

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2011, 2013-2014, 2016-2017
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2011, 2013-2014, 2016-2017
  • CMS Meaningful Use Stage 2 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2011, 2013-2014, 2016-2017

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Utility of Tacrolimus (FK506) for the Prevention of Erectile Dysfunction Following Bilateral Nerve-S...  
    John P Mulhall, Eric A Klein, Kevin Slawin, Peter T Scardino, The Journal of Sexual Medicine
  • Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer  
    Evans JR, Zhao SG, Chang SL, Tomlins SA, Erho N, Sboner A, Schiewer MJ, Spratt DE, Kothari V, Klein EA, Den RB, Dicker AP, Karnes RJ, Yu X, Nguyen PL, Rubin MA, de Bon..., JAMA Oncol, 1/7/2016
  • Whole-exome sequencing of over 4100 men of African ancestry and prostate cancer risk  
    Rand KA, Rohland N, Tandon A, Stram A, Sheng X, Do R, Pasaniuc B, Allen A, Quinque D, Mallick S, Le Marchand L, Kaggwa S, Lubwama A; African Ancestry Prostate Cancer G..., Hum Mol Genet, 1/24/2015

Books/Book Chapters

Lectures

  • Development of a comprehensive cell-free DNA (cfDNA) assay for early detection of multiple tumor types: The Circulating Cell-free Genome Atlas (CCGA) study. 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
  • Biomarkers in Prostate Cancer 
    1/30/2014
  • Prostate Cancer: Past, Present, and Future Perfect. The Dawn of the Precision Medicine Era 
    1/2/2014

Other

Authored Content

  • Influence of 5-Alpha Reductase Inhibitors on Prostate Cancer Detection with MRI: A Matched Cohort StudyJuly 2021

Press Mentions

  • FDA Approves Blood-Based Prostate Cancer Test
    FDA Approves Blood-Based Prostate Cancer TestDecember 3rd, 2025
  • Cleveland Diagnostics’ IsoPSA Secures FDA Approval for Prostate Cancer
    Cleveland Diagnostics’ IsoPSA Secures FDA Approval for Prostate CancerDecember 2nd, 2025
  • FDA Approves New Blood Test for Detection of High-Grade Prostate Cancer
    FDA Approves New Blood Test for Detection of High-Grade Prostate CancerDecember 2nd, 2025

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: